Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow GHRS by emailGet an email when GHRS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GHRS, unsubscribe in one click. Privacy
📣 What GHRS Says Is Next
in 2026 · “We continue to engage with the FDA on the design of the pivotal program, which is intended to replicate the Phase 2b trial, including consideration of recent FDA guidance issued in July 2026, and we continue to target initiation of our pivotal program in 2026.”
Company press release, Aug 6, 2026 · SEC filing
late 2026 · “We continue to target initiation of our global pivotal program in late 2026.”
Company press release, May 14, 2026 · SEC filing
in 2026 · “In 2021, we, with a contract development and manufacturing organization, or CDMO, initiated the development of a proprietary aerosol delivery device for GH001 for use in our pivotal clinical trial program, which we expect to initiate in 2026, and for commercial use.”
Company press release, May 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full GHRS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GHRS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.